Ankit Chothani
Interventional Cardiology · Tulsa, OKNPI 1891052072
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,765 of the $12,903 with a category attached, or 60.2%. 25 manufacturers reported payments, led by Inari Medical, Inc. at 32.8% of the total. Reporting peaked in 2023 at $4,471 and has fallen 57.6% since, to $1,894 in 2025.
Across 158 payments — averaging $81.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$4K
- Medtronic$3K
- Abiomed$3K
- Philips North America LLC$1K
- Penumbra, Inc.$598
- Angiodynamics, Inc.$232
- plus $996 from 19 others
What the payments were for
- Travel & lodging$5,13840%
- Food & beverage$7,76560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 33 | $4,234 |
| Medtronic(2 entities) | 28 | $3,060 |
| Abiomed | 29 | $2,556 |
| Philips North America LLC | 8 | $1,227 |
| Penumbra, Inc. | 5 | $598 |
| Angiodynamics, Inc. | 7 | $232 |
| Abbott | 2 | $160 |
| Amgen | 8 | $136 |
| Actelion Pharmaceuticals US, Inc. | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Novartis | 4 | $67 |
| Alnylam Pharmaceuticals Inc. | 3 | $59 |
| Pfizer | 3 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $41 |
| Johnson & Johnson | 2 | $36 |
| Bard Peripheral Vascular, Inc. | 1 | $32 |
| Imperative Care, Inc | 1 | $30 |
| Boston Scientific | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Stryker | 2 | $28 |
| Cathworks, Inc. | 1 | $23 |
| AstraZeneca | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$4,473
- CT THROMBECTOMY SYSTEM KIT$2,644
- Impella$1,348
- Abre$1,223
- HawkOne$1,187
- (BQ9) Coronary IVUS$950
- Indigo System$529
- CardioMEMS HF System$135
- (4067) Tack Endovascular Systems BTK$125
How this compares
$12,903 in reported general payments places this provider in the 70th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $144,877 |
| EntrestoSacubitril/Valsartan | 64 | $55,689 |
| Repatha SureclickEvolocumab | 55 | $37,921 |
| JardianceEmpagliflozin | 14 | $15,788 |
| FarxigaDapagliflozin Propanediol | 22 | $11,868 |
| BrilintaTicagrelor | 18 | $7,654 |
| ClopidogrelClopidogrel Bisulfate | 402 | $3,776 |
| Metoprolol Succinate | 231 | $2,505 |
| Atorvastatin Calcium | 299 | $2,455 |
| Ranolazine ErRanolazine | 27 | $1,866 |
| Losartan Potassium | 120 | $1,415 |
| Amlodipine Besylate | 140 | $846 |
| Torsemide | 63 | $832 |
| Carvedilol | 104 | $721 |
| Potassium Chloride | 49 | $699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52 | $144,877170 claims |
| NovartisEntresto | $67 | $55,68964 claims |
| AstraZenecaFarxiga, Brilinta | $18 | $19,52240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.